Executive Summary: The Procurement Crisis of 2026As we navigate the second quarter of 2026, the global pharmaceutical intermediate market has entered a phase of "Mirage Stability." While demand for certain bulk commodities appears to be stabilizing, the specialty segment—specifically for Cyclopentan
Executive Summary: The Hidden Cost of "Slow" ChemistryIn the intense surge of the 2026 generic drug market, the primary bottleneck for pharmaceutical companies is no longer intellectual property or clinical data—it is Reactor Throughput. When a multi-ton campaign for an antiviral or cardiovascular A
Executive Summary: The Fallacy of "99% Purity"In the global procurement of pharmaceutical intermediates, the industry standard has long been the "99% Purity" benchmark. However, as we navigate the high-stakes pharmaceutical landscape of 2026, a simple percentage on a Certificate of Analysis (COA) is